Drug Profile
Research programme: anti-infectives - Bristol-Myers Squibb/Merck
Alternative Names: Anti-infectives research programme: - Bristol-Myers Squibb/MerckLatest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals
- Developer Bristol-Myers Squibb; Cubist Pharmaceuticals
- Class
- Mechanism of Action Amino acyl tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 20 Sep 2004 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 02 Oct 2001 This programme is still in active development
- 22 Nov 1999 Preclinical development for Bacterial infections in USA (Unknown route)